MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 -
Germany
MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 -
Germany
This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions
| Offizielle URL: https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2021 | Version: 2027.0.0-ballot.1 | |||
| Active Stand: 2024-12-12 | Maschinenlesbarer Name: MII_CM_Onko_ATC_Transitions_2021 | |||
Diese ConceptMap dokumentiert ausschließlich die ATC-Code-Änderungen von 2020 zu 2021. Im Jahr 2021 erfolgte eine umfassende Reorganisation der ATC-Klassifikation für onkologische Substanzen mit Umkodierung von über 60 Wirkstoffen.
Language: de
Profiles: CRMI Shareable ConceptMap, CRMI Publishable ConceptMap
Mapping from MII VS Onkologie Systemische Therapie Substanzen ATC 2020 to MII VS Onkologie Systemische Therapie Substanzen ATC 2021
Mapping from http://fhir.de/CodeSystem/bfarm/atc (Atc) to http://fhir.de/CodeSystem/bfarm/atc (Atc)
| Source Code | Relationship | Target Code | Comment |
| L01XE01 (Imatinib) | is equivalent to | L01EA01 (Imatinib) | Reklassifizierung zu BCR-ABL Tyrosinkinase-Inhibitoren |
| L01XE06 (Dasatinib) | is equivalent to | L01EA02 (Dasatinib) | |
| L01XE08 (Nilotinib) | is equivalent to | L01EA03 (Nilotinib) | |
| L01XE14 (Bosutinib) | is equivalent to | L01EA04 (Bosutinib) | |
| L01XE24 (Ponatinib) | is equivalent to | L01EA05 (Ponatinib) | |
| L01XE02 (Gefitinib) | is equivalent to | L01EB01 (Gefitinib) | Reklassifizierung zu EGFR Tyrosinkinase-Inhibitoren |
| L01XE03 (Erlotinib) | is equivalent to | L01EB02 (Erlotinib) | |
| L01XE13 (Afatinib) | is equivalent to | L01EB03 (Afatinib) | |
| L01XE35 (Osimertinib) | is equivalent to | L01EB04 (Osimertinib) | |
| L01XE15 (Vemurafenib) | is equivalent to | L01EC01 (Vemurafenib) | Reklassifizierung zu BRAF-Inhibitoren |
| L01XE23 (Dabrafenib) | is equivalent to | L01EC02 (Dabrafenib) | |
| L01XE46 (Encorafenib) | is equivalent to | L01EC03 (Encorafenib) | |
| L01XE16 (Crizotinib) | is equivalent to | L01ED01 (Crizotinib) | Reklassifizierung zu ALK-Inhibitoren |
| L01XE28 (Ceritinib) | is equivalent to | L01ED02 (Ceritinib) | |
| L01XE36 (Alectinib) | is equivalent to | L01ED03 (Alectinib) | |
| L01XE43 (Brigatinib) | is equivalent to | L01ED04 (Brigatinib) | |
| L01XE44 (Lorlatinib) | is equivalent to | L01ED05 (Lorlatinib) | |
| L01XE25 (Trametinib) | is equivalent to | L01EE01 (Trametinib) | Reklassifizierung zu MEK-Inhibitoren |
| L01XE38 (Cobimetinib) | is equivalent to | L01EE02 (Cobimetinib) | |
| L01XE41 (Binimetinib) | is equivalent to | L01EE03 (Binimetinib) | |
| L01XE33 (Palbociclib) | is equivalent to | L01EF01 (Palbociclib) | Reklassifizierung zu CDK4/6-Inhibitoren |
| L01XE42 (Ribociclib) | is equivalent to | L01EF02 (Ribociclib) | |
| L01XE50 (Abemaciclib) | is equivalent to | L01EF03 (Abemaciclib) | |
| L01XE09 (Temsirolimus) | is equivalent to | L01EG01 (Temsirolimus) | Reklassifizierung zu mTOR-Inhibitoren |
| L01XE10 (Everolimus) | is equivalent to | L01EG02 (Everolimus) | |
| L01XE07 (Lapatinib) | is equivalent to | L01EH01 (Lapatinib) | Reklassifizierung zu HER2-Inhibitoren |
| L01XE45 (Neratinib) | is equivalent to | L01EH02 (Neratinib) | |
| L01XE18 (Ruxolitinib) | is equivalent to | L01EJ01 (Ruxolitinib) | Reklassifizierung zu JAK-Inhibitoren |
| L01XE17 (Axitinib) | is equivalent to | L01EK01 (Axitinib) | Reklassifizierung zu VEGFR-Inhibitoren |
| L01XE34 (Tivozanib) | is equivalent to | L01EK03 (Tivozanib) | |
| L01XE27 (Ibrutinib) | is equivalent to | L01EL01 (Ibrutinib) | Reklassifizierung zu BTK-Inhibitoren |
| L01XE51 (Acalabrutinib) | is equivalent to | L01EL02 (Acalabrutinib) | |
| L01XX47 (Idelalisib) | is equivalent to | L01EM01 (Idelalisib) | Reklassifizierung zu PI3K-Inhibitoren |
| L01XX61 (Copanlisib) | is equivalent to | L01EM02 (Copanlisib) | |
| L01XE04 (Sunitinib) | is equivalent to | L01EX01 (Sunitinib) | Reklassifizierung zu andere Proteinkinase-Inhibitoren |
| L01XE05 (Sorafenib) | is equivalent to | L01EX02 (Sorafenib) | |
| L01XE12 (Vandetanib) | is equivalent to | L01EX04 (Vandetanib) | |
| L01XE21 (Regorafenib) | is equivalent to | L01EX05 (Regorafenib) | |
| L01XE26 (Cabozantinib) | is equivalent to | L01EX07 (Cabozantinib) | |
| L01XE29 (Lenvatinib) | is equivalent to | L01EX08 (Lenvatinib) | |
| L01XE31 (Nintedanib) | is equivalent to | L01EX09 (Nintedanib) | |
| L01XE39 (Midostaurin) | is equivalent to | L01EX10 (Midostaurin) | |
| L01XE52 (Quizartinib) | is equivalent to | L01EX11 (Quizartinib) | |
| L01XE53 (Larotrectinib) | is equivalent to | L01EX12 (Larotrectinib) | |
| L01XE54 (Gilteritinib) | is equivalent to | L01EX13 (Gilteritinib) | |
| L01XX14 (Tretinoin) | is equivalent to | L01XF01 (Tretinoin) | Reklassifizierung zu Retinoide |
| L01XX22 (Alitretinoin) | is equivalent to | L01XF02 (Alitretinoin) | |
| L01XX25 (Bexaroten) | is equivalent to | L01XF03 (Bexaroten) | |
| L01XX32 (Bortezomib) | is equivalent to | L01XG01 (Bortezomib) | Reklassifizierung zu Proteasom-Inhibitoren |
| L01XX45 (Carfilzomib) | is equivalent to | L01XG02 (Carfilzomib) | |
| L01XX50 (Ixazomib) | is equivalent to | L01XG03 (Ixazomib) | |
| L01XX38 (Vorinostat) | is equivalent to | L01XH01 (Vorinostat) | Reklassifizierung zu Histon-Deacetylase-Inhibitoren |
| L01XX39 (Romidepsin) | is equivalent to | L01XH02 (Romidepsin) | |
| L01XX42 (Panobinostat) | is equivalent to | L01XH03 (Panobinostat) | |
| L01XX49 (Belinostat) | is equivalent to | L01XH04 (Belinostat) | |
| L01XX43 (Vismodegib) | is equivalent to | L01XJ01 (Vismodegib) | Reklassifizierung zu Hedgehog-Signalweg-Inhibitoren |
| L01XX63 (Glasdegib) | is equivalent to | L01XJ03 (Glasdegib) | |
| L01XX46 (Olaparib) | is equivalent to | L01XK01 (Olaparib) | Reklassifizierung zu PARP-Inhibitoren |
| L01XX54 (Niraparib) | is equivalent to | L01XK02 (Niraparib) | |
| L01XX60 (Talazoparib) | is equivalent to | L01XK04 (Talazoparib) | |
| L01XX17 (Topotecan) | is equivalent to | L01CE01 (Topotecan) | Reklassifizierung zu Topoisomerase-I-Inhibitoren |
| L01XX19 (Irinotecan) | is equivalent to | L01CE02 (Irinotecan) |